Revenio Group Oyj, provides ophthalmological devices and software solutions for the diagnosis of glaucoma, macular degeneration, and diabetic retinopathy in Finland, the United States, and internationally. The company offers iCare IC100, ST500, and IC200 tonometers; iCare HOME2, a tonometer to measure eye pressure; iCare Sensors that are accessories of iCare tonometer for measuring intraocular pressure (IOP); iCare TONOVET Pro, a tonometer designed for use in surgical or emergency settings; and iCare TONOVET Plus tonometer, which is used by veterinarians, ophthalmologists and other personnel to measure intraocular pressure in animal patients. It also provides imaging devices comprising iCare EIDON, a device with confocal retinal imaging; iCare DRSplus, a device for pupil imaging; and iCare COMPASS, which provides fundus perimetry with true-color confocal retinal images. In addition, the company offers iCare ILLUME, a screening software that helps to detect the early signs of diabetic retinopathy, age-related macular degeneration, and glaucoma using artificial intelligence; iCare CLINIC cloud software to store long-term IOP data; and Oculo, an eye care software platform, which combines clinical communication, telehealth, remote patient monitoring and data analytics capabilities. Revenio Group Oyj was incorporated in 2001 and is based in Vantaa, Finland.…
What Is Novartis (SWX:NOVN) Gaining From Its PMR Approval And ADC Deal?
Revenio Group (HEL: REG1V) is listed on Nasdaq Helsinki, where its shares trade in EUR. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 744 employees.
The shares were at 9.040 EUR on 20 November 2026, down 61.5% over 52 weeks. Its 52-week range is 8.740 EUR to 23.85 EUR: the price is 62.1% below the high and 3.4% above the low.
At a market capitalisation of 379.96M EUR, it trades at 24.4 times trailing earnings and 14.4 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, so REG1V is valued in line with them.
Revenio Group reports return on equity of 15.2%, an operating margin of 15.3% and revenue up 127.8% year over year.
Its debt exceeds its cash by 235.80M EUR, a debt-to-equity ratio of 0.10. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 4 analysts cover the stock, with an average rating of Buy; their mean price target of 11.68 EUR is 29.1% above the current price. The next earnings report is expected on 10 February 2027.